Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
Amyloid nomenclature 2022: update, novel proteins, and recommendations by the International Society of Amyloidosis (ISA) Nomenclature Committee
复制标题
DOI：
10.1080/13506129.2022.2147636
复制
发表时间：
2022-11-23
影响因子：
5.5
通讯作者：
Westermark, Per
中科院分区：
文献类型：
--
作者：
Buxbaum, Joel N.;Dispenzieri, Angela;Westermark, Per
国际淀粉样变性学会命名委员会于2022年9月和10月召开了第18届淀粉样变性国际研讨会，讨论了这一升级的命名建议。命名原则保持不变，但关于细胞内蛋白聚集体的重要性和不同性质的讨论正在进行，特别是与神经退行性疾病有关的聚集体。六种新的蛋白被添加到人类淀粉样纤维蛋白列表中。其中，三种是多肽激素，两种是目前使用的肽药物，使得已知的医源性淀粉样蛋白形式有四种，都表现为注射部位的皮下结节。第六种新的淀粉样蛋白是跨膜106B蛋白，在与额颞叶痴呆相关的疾病中形成细胞内淀粉样蛋白原纤维。目前已知的人类淀粉样蛋白纤维有42种。
The Nomenclature Committee of the International Society of Amyloidosis met at the XVIII International Symposium on Amyloidosis in September and virtually in October 2022 with discussions resulting in this upgraded nomenclature recommendation. The nomenclature principles remain unchanged but there is an ongoing discussion regarding the importance and varying nature of intracellular protein aggregates, particularly those associated with neurodegenerative diseases. Six novel proteins were added to the list of human amyloid fibril proteins. Of these, three are polypeptide hormones and two currently utilised peptide drugs, making the number of known iatrogenic amyloid forms four, all appearing as subcutaneous nodules at the injection site. The sixth novel amyloid fibril protein is the transmembrane 106B protein, forming intracellular amyloid fibrils in disorders associated with frontotemporal dementia. The number of known human amyloid fibril proteins is now 42.